Cellular immunotherapy for hematological malignancy: recent progress and future perspectives  

作　　者：Zhengli Xu Xiaojun Huang 

机构地区：[1]Peking University People’s Hospital,Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Beijing 100044,China

出　　处：《Cancer Biology & Medicine》2021年第4期966-980,共15页癌症生物学与医学（英文版）

基　　金：This work was partly supported by the Foundation for Innovative Research Groups of the National Natural Science Foundation of China(Grant No.81621001);The Key Program of National Natural Science Foundation of China(Grant No.81930004);The National Key Research and Development Program of China(Grant No.2017YFA0104500).

摘　　要：Advancements in the field of cellular immunotherapy have accelerated in recent years and have changed the treatment landscape for a variety of hematologic malignancies.Cellular immunotherapy strategies exploit the patient’s immune system to kill cancer cells.The successful use of CD19 chimeric antigen receptor(CAR)T-cells in treating B-cell malignancies is the paradigm of this revolution,and numerous ongoing studies are investigating and extending this approach to other malignancies.However,resistance to CAR-Tcell therapy and non-durable efficacy have prevented CAR-T-cells from becoming the ultimate therapy.Because natural killer(NK)cells play an essential role in antitumor immunity,adoptively transferred allogeneic NK and CAR-modified NK cell therapy has been attempted in certain disease subgroups.Allogenic hematopoietic stem cell transplantation(allo-HSCT)is the oldest form of cellular immunotherapy and the only curative option for hematologic malignancies.Historically,the breadth of application of allo-HSCT has been limited by a lack of identical sibling donors(ISDs).However,great strides have recently been made in the success of haploidentical allografts worldwide,which enable everyone to have a donor.Haploidentical donors can achieve comparable outcomes to those of ISDs and even better outcomes in certain circumstances because of a stronger graft vs.tumor effect.Currently,novel strategies such as CAR-T or NK-based immunotherapy can be applied as a complement to allo-HSCT for curative effects,particularly in refractory cases.Here,we introduce the developments in cellular immunotherapy in hematology.

关 键 词：Cellular immunotherapy HEMATOLOGIC CAR-T NK stem cell transplantation 

分 类 号：R730.51[医药卫生—肿瘤] R733[医药卫生—临床医学]